Skip to main content
Caplight Logo









Calluna Pharma

Calluna Pharma

Private
OsloHealthcare & Life Scienceshttps://www.callunapharma.com/

Last Round

Series A

Jan 23, 2024

Total Funding Raised

$81.3M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Calluna Pharma is a clinical-stage biotechnology company developing a pipeline of selective antibodies to treat inflammatory and fibrotic diseases by targeting the innate immune system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodybiotechnologydrug discoveryinflammatory diseasefibrotic diseasebiopharmaclinical-stage biotechtherapeutic candidateclinical trialsIPFidiopathic pulmonary fibrosischronic kidney diseaseDAMPsdamage-associated molecular patternsdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Calluna Pharma Comparables

Compare Calluna Pharma with similar companies based on industry and business-model similarity.

Calluna Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mediar Therapeutics
80%
Endeavor BioMedicines
74%
Ikaika Therapeutics
68%

Calluna Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 23, 2024

Key People

Founding team and executive leadership

Jonas Hallén

Chief Medical Officer Co-Founder

Founding Team

Mark Gaffney

Chief Executive Officer & Board Member

Executive Team

Calluna Pharma Investors

Notable investors and investment history

Calluna Pharma investors
InvestorRounds
ForbionSeries A
InvestinorSeries A
P53 InvestSeries A
SarsiaSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Monthly visitors increased 90% MoM.

  • Dec 16, 2025

    Gijs van den Brink appointed as independent director.

Calluna Pharma Filings

Explore SEC and related filing metadata, where available.

Calluna Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Calluna Pharma's valuation, stock price, and market status.

Is Calluna Pharma a public or private company?

Calluna Pharma is a private company.

What is the current stock price of Calluna Pharma?

Calluna Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Calluna Pharma worth (valuation)?

Valuation information for Calluna Pharma is not publicly available.

Can I buy Calluna Pharma stock?

Calluna Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Calluna Pharma's last funding round?

Calluna Pharma's most recent funding round was Series A on January 23, 2024.

Who are the main investors in Calluna Pharma?

Key investors in Calluna Pharma include Investinor, Sarsia.

Will Calluna Pharma IPO soon?

No public IPO plans have been announced for Calluna Pharma.

How can I track Calluna Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Calluna Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOslo
Employee Range23
Year Founded2024
Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?